Autoimmune Disease Diagnostics Market Worth Scope $5.0 Billion By 2025

San Francisco, 09 Oct 2019 - The global autoimmune disease diagnostics market is expected to reach a value of USD 5.0 billion by 2025, based on a new report by Grand View Research, Inc. Government organizations along with related associations strive to curb such high healthcare costs and simultaneously provide improved diagnostic and therapeutic solutions to the patients. This has resulted in increased funding by the NIH for R&D programs related to autoimmune diseases. 

Moreover, presence of favorable government initiatives aimed at curbing incidence of these diseases and developing viable diagnostic & treatment options is expected to drive market growth over the forecast period.

Growing volume of autoimmune diagnostic procedures has heightened the need for instruments and facilities rendering faster and effective results. In an attempt to cater to ever-increasing procedure volumes, diagnostic laboratories are rapidly moving toward automation. Lab automation helps decrease workload via rapid turnaround times and helps generate standardized & reproducible results.


Further key findings from the study suggest:
  • Localized autoimmune disease diagnostics was the largest segment in 2015 owing to high usage for type 1 diabetes and idiopathic thrombocytopenic purpura
  • Type 1 diabetes is estimated to grow at a significant growth rate of over 4.0% in localized disease type segment
  • Systemic disease diagnostics is anticipated to witness lucrative CAGR of around 5.0% over the forecast period due to increasing R&D for the development of novel diagnostic biomarkers for the treatment of rheumatoid arthritis and systemic lupus erythematosus
  • Rheumatoid arthritis is one of the most recurring autoimmune disorders further demanding high amount of rapid diagnostics for exploring better alternative treatments
  • North America was the largest regional market in 2015. High market penetration rate of technologically advanced products and increased lab automation rate are some of the factors contributing to its large share
  • Asia Pacific region is anticipated to grow at the fastest CAGR of above 4.0% over the forecast period owing to increasing focus on type 1 diabetes diagnosis
  • Some of the key players of this market include F. Hoffmann-La Roche Ltd; Siemens Healthineers; Abbott Laboratories; Beckman Coulter, Inc.; SQI Diagnostics; Quest Diagnostics; EUROIMMUN AG; AESKU. Diagnostics; Inova Diagnostics, Inc.; Crescendo Bioscience, Inc.; bioMerieux SA; Bio-Rad Laboratories, Inc.; and Hemagen Diagnostics, Inc.
About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
For More Information: www.grandviewresearch.com
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

mHealth Apps Market Is Projected To Reach $236.0 Billion By 2026

The global  mHealth apps market  size is expected to reach USD 236.0 billion by 2026, according to a new report by Grand View Research, In...